Teva Pharmaceutical Industries Ltd. has entered into a funding agreement with Royalty Pharma plc to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408, for the treatment of vitiligo and other autoimmune diseases. Under the terms of the agreement, Royalty Pharma will provide up to $500 million to support ongoing research and development, including $75 million to fund a Phase 2b study starting in 2026. Pending positive results from this study, Royalty Pharma has the option to invest an additional $425 million to support Phase 3 development. If TEV-'408 is approved and launched, Teva will pay Royalty Pharma a milestone payment and royalties on global net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001158694-en) on January 11, 2026, and is solely responsible for the information contained therein.